Live tape
Top 8, mentions 7d14,356NVDA4,865 mentions▲ +0.04GOOGL2,063 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,108 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

ANIP

NASDAQ

ANI Pharmaceuticals (ANIP)

67.82 USD +0.53% vs prior close Nov 9, 2026
ANI Pharmaceuticals, Inc. price graph
63 sessions
80 65 12 Aug 9 Nov

The line runs 75 USD on 12 August through 67.82 USD on 9 November, on a scale from 65 to 80. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
1.5B USD
P/E (TTM)
13.6
Revenue, year to Dec 2025
883.4M USD
EPS, diluted, year to Dec 2025
3.32 USD
52-week range
67.46 USD – 94.58 USD
Avg volume
20.8K

as of Nov 9, 2026

Have ANI Pharmaceuticals (ANIP) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, ANI Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Oct 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 29 Oct 2026

0buys
10sells
$1.98Mnet sold
1other filings
Have ANI Pharmaceuticals (ANIP) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
29 Oct 2026CAREY STEPHEN P.SVP & CFOSell2,850208K USD
15 Oct 2026Lalwani NikhilPRESIDENT & CEOSell5,400388K USD
13 Oct 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sell50037K USD
29 Sep 2026CAREY STEPHEN P.SVP & CFOSell2,850208K USD
15 Sep 2026Lalwani NikhilPRESIDENT & CEOSell5,400383K USD
14 Sep 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sell50035K USD
11 Sep 2026Thoma JeanneDirectorSell1,00072K USD
31 Aug 2026CAREY STEPHEN P.SVP & CFOSell2,850207K USD
25 Aug 2026Lalwani NikhilPRESIDENT & CEOSell5,400401K USD
13 Aug 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sell50038K USD
Sold10 open-market sales27,250$1.98M
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have ANI Pharmaceuticals (ANIP) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
19 Aug 2026Gosebruch Henry ODirectorAward6,662

Which funds hold ANI Pharmaceuticals (ANIP)?

7 of the 45 institutional funds we track reported a ANI Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 84.1M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold ANI Pharmaceuticals (ANIP)?
FundPositionSharesValueShares q/q
Millennium ManagementHeld (±25%)507,20742.0M USD−14.3%
D. E. Shaw & Co.Held (±25%)174,73214.5M USD−18.1%
Citadel AdvisorsHeld (±25%)96,0828.0M USD−16.5%
Man GroupTrimmed80,4966.7M USD−61.4%
Two Sigma InvestmentsTrimmed64,2325.3M USD−33.7%
Renaissance TechnologiesTrimmed63,7005.3M USD−65.8%
AQR Capital ManagementAdded29,5002.4M USD+56.6%

What has been filed or recorded for ANI Pharmaceuticals (ANIP)?

The filings we hold for ANI Pharmaceuticals, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for ANI Pharmaceuticals (ANIP)?
And
09 Oct 2026Fails to deliverShares failed to deliver16 shares1K USD notional · <0.001% of shares out
06 Oct 2026Fails to deliverShares failed to deliver450 shares33K USD notional · 0.002% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 1.51 USD
30 Sep 2026FinancialsTotal assets1.6B USDat period end
30 Sep 2026FinancialsTotal equity637.1M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 1.05 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 1.28 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 3.32 USD
31 Dec 2025FinancialsRevenue883.4M USDfiscal year
31 Dec 2025FinancialsNet income78.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS3.32 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 1.13 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.36 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.69 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.04 USD

What do people ask about ANI Pharmaceuticals (ANIP)?

From live data
What did ANI Pharmaceuticals shares close at?67.82

ANI Pharmaceuticals closed at 67.82 USD on 9 Nov 2026, up 0.53% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is ANI Pharmaceuticals’ market cap?1.5B

ANI Pharmaceuticals is worth 1.5B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is ANI Pharmaceuticals’ P/E ratio?13.6

ANI Pharmaceuticals has a price-to-earnings ratio of 13.6, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is ANI Pharmaceuticals’ revenue?883.4M

ANI Pharmaceuticals reported revenue of 883.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have ANI Pharmaceuticals insiders bought or sold shares recently?10 sales

In the 90 days to 10 Nov 2026, ANI Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Oct 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own ANI Pharmaceuticals?7 of 45

7 of the 45 funds we track reported a ANI Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, D. E. Shaw & Co. and Citadel Advisors. See Funds

When did ANI Pharmaceuticals last report earnings?1.51

ANI Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 1.51 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings